Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/5534
Title: No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Authors: Camargo, Elaine Aparecida de
Silva, Glenda Nicioli da
Gobette, Camila Pereira
Marcondes, João Paulo de Castro
Salvadori, Daisy Maria Fávero
Keywords: Gene expression profile
Genotoxicity
Issue Date: 2013
Citation: CAMARGO, E. A. de et al. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine. Asian Pacific Journal of Cancer Prevention, v. 14, p. 5941-5948, 2013. Disponível em: <http://koreascience.or.kr/article/JAKO201305981337960.page>. Acesso em: 22 mai. 2015.
Abstract: Tumor response to antineoplastic drugs is not always predictable. This is also true for bladder carcinoma, a highly recurrent neoplasia. Currently, the combination of cisplatin and gemcitabine is well accepted as a standard protocol for treating bladder carcinoma. However, in some cases, this treatment protocol causes harmful side effects. Therefore, we investigated the roles of the genes TP53, RASSF1A (a tumor suppressor gene) and hMLH1 (a gene involved in the mismatch repair pathway) in cell susceptibility to cisplatin/gemcitabine treatment. Two bladder transitional carcinoma cell (TCC) lines, RT4 (wild-type TP53) and 5637 (mutated TP53), were used in this study. First, we evaluated whether the genotoxic potential of cisplatin/gemcitabine was dependent on TP53 status. Then, we evaluated whether the two antineoplastic drugs modulated RASSF1A and hMLH1 expression in the two cell lines. Increased DNA damage was observed in both cell lines after treatment with cisplatin or gemcitabine and with the two drugs simultaneously, as depicted by the comet assay. A lack of RASSF1A expression and hypermethylation of its promoter were observed before and after treatment in both cell lines. On the other hand, hMLH1 downregulation, unrelated to methylation status, was observed in RT4 cells after treatment with cisplatin or with cisplatin and gemcitabine simultaneously (wild-type TP53); in 5637 cells, hMLH1 was upregulated only after treatment with gemcitabine. In conclusion, the three treatment protocols were genotoxic, independent of TP53 status. However, cisplatin was the most effective, causing the highest level of DNA damage in both wild-type and mutated TP53 cells. Gemcitabine was the least genotoxic agent in both cell lines. Furthermore, no relationship was observed between the amount of DNA damage and the level of hMLH1 and RASSF1A expression. Therefore, other alternative pathways might be involved in cisplatin and gemcitabine genotoxicity in these two bladder cancer cell lines.
URI: http://www.repositorio.ufop.br/handle/123456789/5534
metadata.dc.identifier.doi: https://doi.org/10.7314/apjcp.2013.14.10.5941
ISSN: 1513-7368
metadata.dc.rights.license: Papers published by APJCP are published and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by/3.0/), under which authors reserve the copyright for their content; however, they permit anyone unrestricted non-commercial use as long as the original authors and source are cited. Fonte: APJCP <http://www.apocpcontrol.org/page/information.php>. Acesso em: 22 maio 2015.
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_RelationshipBetweenAmount.pdf737,79 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.